Top Tweets for #oatd02

Molecure @molecure_sa

4 months ago

#Molecure has completed the dose-limiting toxicity (DLT) observation period in all patients treated with #OATD02 at the 40 mg QD dose level. Following review of the data collected so far, and with approval from the SRC, the study has progressed to the 80 mg QD dose level! 📣🌍

molecure_sa's tweet photo. #Molecure has completed the dose-limiting toxicity (DLT) observation period in all patients treated with #OATD02 at the 40 mg QD dose level. Following review of the data collected so far, and with approval from the SRC, the study has progressed to the 80 mg QD dose level! 📣🌍 https://t.co/qTzpN3SDlO

0

5

0

0

438

Molecure @molecure_sa

about 1 year ago

Our Head of Medicinal Chemistry, Roman Błaszczyk, presented at the XII Medicinal Chemistry Symposium in Lublin on “Boronic Acids as Arginase Inhibitors: Discovery and Development of the Polish Experimental Immuno-Oncology Drug #OATD02”🔬

molecure_sa's tweet photo. Our Head of Medicinal Chemistry, Roman Błaszczyk, presented at the XII Medicinal Chemistry Symposium in Lublin on “Boronic Acids as Arginase Inhibitors: Discovery and Development of the Polish Experimental Immuno-Oncology Drug #OATD02”🔬 https://t.co/D3RmOfnVka

0

2

0

0

255

Molecure @molecure_sa

over 1 year ago

🎙️ Marcin Szumowski spoke to @PAPBiznes about the accelerated dose escalation of #OATD02 in the ongoing Phase I clinical trial and shared updates on the company’s clinical programs and strategic plans 💊 👉 Read the full interview here: https://t.co/iv5YHhogqE

molecure_sa's tweet photo. 🎙️ Marcin Szumowski spoke to @PAPBiznes about the accelerated dose escalation of #OATD02 in the ongoing Phase I clinical trial and shared updates on the company’s clinical programs and strategic plans 💊

👉 Read the full interview here: https://t.co/iv5YHhogqE https://t.co/659rCEdPwh

1

5

0

2

380

Molecure @molecure_sa

almost 2 years ago

We'll participate in the #BIOEurope Conference in Stockholm next week! ✨ Our team: CEO Marcin Szumowski, CSO Zbigniew Zasłona and Business Development Manager Maurycy Zieliński, will hold numerous meetings to present our research on #OATD01, #OATD02 and our #mRNA platform 🔬

molecure_sa's tweet photo. We'll participate in the #BIOEurope Conference in Stockholm next week! ✨

Our team: CEO Marcin Szumowski, CSO Zbigniew Zasłona and Business Development Manager Maurycy Zieliński, will hold numerous meetings to present our research on #OATD01, #OATD02 and our #mRNA platform 🔬 https://t.co/l7VOzbvbC5

0

5

0

0

310

Molecure @molecure_sa

about 2 years ago

🎙️ Listen to an interview with our Chief Scientific Officer, Zbigniew Zasłona, during the #PHASE2024 conference with the @strefainw #OATD01, #OATD02 and much more! 🤝 Check it out here 👉 https://t.co/1xlSfYQ7EI

molecure_sa's tweet photo. 🎙️ Listen to an interview with our Chief Scientific Officer, Zbigniew Zasłona, during the #PHASE2024 conference with the @strefainw

#OATD01, #OATD02 and much more! 🤝 Check it out here 👉 https://t.co/1xlSfYQ7EI https://t.co/wciwFymHOw

0

5

0

0

287

Molecure @molecure_sa

about 2 years ago

🎤Our Head of Medicinal Chemistry, Roman Błaszczyk, gave a presentation on the Arginase 1/2 Inhibitor #OATD02: From Discovery to Clinical Trials in Cancer Immunotherapy (LE075) 💉#EFMCISMC24 #medchem

molecure_sa's tweet photo. 🎤Our Head of Medicinal Chemistry, Roman Błaszczyk, gave a presentation on the Arginase 1/2 Inhibitor #OATD02: From Discovery to Clinical Trials in Cancer Immunotherapy (LE075) 💉#EFMCISMC24 #medchem https://t.co/IHDGyzWeyt

1

3

0

0

224

Molecure @molecure_sa

almost 3 years ago

The latest developments of #OATD02 from #Molecure's collaboration with CeMOS. With advanced MALDI-MSI technology provided by EU-OPENSCREEN, we visualized metabolic alterations induced by OATD-02 💊 Find out more here: https://t.co/8lLep0maVS

molecure_sa's tweet photo. The latest developments of #OATD02 from #Molecure's collaboration with CeMOS. With advanced MALDI-MSI technology provided by EU-OPENSCREEN, we visualized metabolic alterations induced by OATD-02 💊

Find out more here:
https://t.co/8lLep0maVS https://t.co/gmm8KQrxbr

0

8

2

0

629

Molecure @molecure_sa

almost 3 years ago

1st anniversary of Polish regulator approval for #OATD02 clinical trial! Reflecting on the year: First patient enrolled in March; Now in 3rd dose level (10 mg), gearing up for 4th dose level (20 mg); 2 successful roll-over study enrollments since August.

molecure_sa's tweet photo. 1st anniversary of Polish regulator approval for #OATD02 clinical trial!
Reflecting on the year: First patient enrolled in March; Now in 3rd dose level (10 mg), gearing up for 4th dose level (20 mg); 2 successful roll-over study enrollments since August. https://t.co/nuWXk17ISU

0

7

1

0

754

Molecure @molecure_sa

almost 3 years ago

This Pancreatic Cancer Awareness Month, let's join forces to spread awareness, support those affected, and continue advancing breakthroughs like #OATD02 that bring hope to the fight against cancer. 🌍💜

molecure_sa's tweet photo. This Pancreatic Cancer Awareness Month, let's join forces to spread awareness, support those affected, and continue advancing breakthroughs like #OATD02 that bring hope to the fight against cancer. 🌍💜 https://t.co/bsw3pxFgRX

0

6

1

0

2K

Molecure @molecure_sa

almost 3 years ago

Our Medical Director, Marta Dudek and Chief Medical Officer, Samson Fung were delighted to have attended #ESMO23 in Madrid 🇪🇸. Marta presented a poster on the first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of #OATD02.

molecure_sa's tweet photo. Our Medical Director, Marta Dudek and Chief Medical Officer, Samson Fung were delighted to have attended #ESMO23 in Madrid 🇪🇸. Marta presented a poster on the first-in-human phase I study to evaluate safety, tolerability and antineoplastic activity of #OATD02. https://t.co/olKa6gotdK

0

8

1

0

686

Molecure @molecure_sa

about 3 years ago

September has been a busy month for #Molecure. We attended 7️⃣conferences and shared key data 🗝 on our first in class compounds, #OATD01 for sarcoidosis & #OATD02 for cancer, offering potential treatments options for patients. More about Molecure ⬇ https://t.co/qzl30X5gP9

molecure_sa's tweet photo. September has been a busy month for #Molecure. We attended 7️⃣conferences and shared key data 🗝 on our first in class compounds, #OATD01 for sarcoidosis & #OATD02 for cancer, offering potential treatments options for patients.

More about Molecure ⬇
https://t.co/qzl30X5gP9 https://t.co/1WFNEfox7l

0

5

0

0

618

Molecure @molecure_sa

about 3 years ago

We are proud to announce a member of the #MolecureTeam - Roman Błaszczyk - will be presenting the story behind the #OATD02 molecule discovery and development during the "EUROPEAN DRUG DISCOVERY INNOVATION & OUTSOURCING PROGRAMME" in Barcelona🇪🇸. More: https://t.co/9g3QzfqGWv

molecure_sa's tweet photo. We are proud to announce a member of the #MolecureTeam - Roman Błaszczyk - will be presenting the story behind the #OATD02 molecule discovery and development during the "EUROPEAN DRUG DISCOVERY INNOVATION & OUTSOURCING PROGRAMME" in Barcelona🇪🇸.

More:
https://t.co/9g3QzfqGWv https://t.co/88tzlu0jMS

0

10

0

0

308

Molecure @molecure_sa

about 3 years ago

#MolecureTeam has published🖋️a new article in the Applied Sciences🔥. Our authors described the analytical method for selective determination of #OATD02 by high-performance liquid chromatography with post-column derivatization and fluorescence detection. https://t.co/7hnKyfBP4v

molecure_sa's tweet photo. #MolecureTeam has published🖋️a new article in the Applied Sciences🔥. Our authors described the analytical method for selective determination of #OATD02 by high-performance liquid chromatography with post-column derivatization and fluorescence detection.

https://t.co/7hnKyfBP4v https://t.co/og92SKu6bu

0

9

0

0

610

Molecure @molecure_sa

about 3 years ago

For over a decade at #Molecure, we have been dedicated to searching🔎and developing first-in-class small molecule drugs💊. Watch the video 🎦 and learn more‼️ 👉Join us to revolutionize biotechnology! 🇵🇱 https://t.co/L0hazApvnp 🇬🇧 https://t.co/UmvLFnvc6b #OATD01 #OATD02 #mRNA

molecure_sa's tweet photo. For over a decade at #Molecure, we have been dedicated to searching🔎and developing first-in-class small molecule drugs💊. Watch the video 🎦 and learn more‼️

👉Join us to revolutionize biotechnology!

🇵🇱 https://t.co/L0hazApvnp
🇬🇧 https://t.co/UmvLFnvc6b
#OATD01 #OATD02 #mRNA https://t.co/xYA3aIikN3

0

9

1

0

727

Molecure @molecure_sa

about 3 years ago

We made it🔝Our article on arginase 1/2 inhibitor #OATD02 is highlighted as the cover story of the latest issue of Molecular Cancer Therapeutics, the official journal 📰 of the @AACR ‼️  Learn more https://t.co/oGapfdLt8U #Molecure #CancerResearch #ARG1 #FDA #molecule

0

12

4

0

845

Molecure @molecure_sa

about 3 years ago

🔝We successfully closed the SPO (Secondary Public Offering) worth PLN 50 million gross‼️ We would like to thank🤝 all investors for their trust in our startegy and growth prospects. Learn more 🇵🇱 https://t.co/B1Ul5YvR1P 🇬🇧 https://t.co/7JlVFUas2Z #OATD01 #OATD02 #Molecure

molecure_sa's tweet photo. 🔝We successfully closed the SPO (Secondary Public Offering) worth PLN 50 million gross‼️

We would like to thank🤝 all investors for their trust in our startegy and growth prospects.

Learn more
🇵🇱 https://t.co/B1Ul5YvR1P
🇬🇧 https://t.co/7JlVFUas2Z

#OATD01 #OATD02 #Molecure https://t.co/tW7LymoTtG

0

8

0

0

611

Molecure @molecure_sa

over 3 years ago

Greetings from Dusseldorf! 🇩🇪 #Molecure is actively participating in the 51st International Symposium of #HPLC and Related Techniques! Elżbieta Sobolewska, our chemist analyst, is presenting a poster with analytical results regarding the molecule #OATD02. #HPLC2023

molecure_sa's tweet photo. Greetings from Dusseldorf! 🇩🇪

#Molecure is actively participating in the 51st International Symposium of #HPLC and Related Techniques! Elżbieta Sobolewska, our chemist analyst, is presenting a poster with analytical results regarding the molecule #OATD02.

#HPLC2023 https://t.co/Isi1ok042R

0

10

0

0

1K

Molecure @molecure_sa

over 3 years ago

Last week our CEO, Marcin Szumowski was delighted to present at LSX in London 🇬🇧. Marcin spoke a.o. about the key factors underlying Molecure's success as well as highlighting its rapidly advancing first in class clinical pipeline including #OATD01 and #OATD02.

molecure_sa's tweet photo. Last week our CEO, Marcin Szumowski was delighted to present at LSX in London 🇬🇧.

Marcin spoke a.o. about the key factors underlying Molecure's success as well as highlighting its rapidly advancing first in class clinical pipeline including #OATD01 and #OATD02. https://t.co/ON3DnsJ6ml

0

6

1

0

474

Molecure @molecure_sa

over 3 years ago

Our CEO, Marcin Szumowski, and Director of Business Development & Licensing, Nicolas Beuzen, enjoy meetings new industry peers to discuss Molecure and our recent progress with #OATD02 💊 at #BioEuropeSpring. #biotech #biotechnology Connect ⬇ https://t.co/qZ6a8Kpouw

molecure_sa's tweet photo. Our CEO, Marcin Szumowski, and Director of Business Development & Licensing, Nicolas Beuzen, enjoy meetings new industry peers to discuss Molecure and our recent progress with #OATD02 💊 at #BioEuropeSpring.

#biotech #biotechnology

Connect ⬇
https://t.co/qZ6a8Kpouw https://t.co/lMmow65BTI

0

14

0

0

750

Molecure @molecure_sa

over 3 years ago

Our recent paper on #OATD02 💊, a combined ARG1/ARG2 inhibitor discovered at #Molecure, has been published 🖋️ in Molecular Cancer Therapeutics @MCT_AACR, a journal of the American Association for Cancer Research. Read the full study here: https://t.co/5V35E7gc6R

molecure_sa's tweet photo. Our recent paper on #OATD02 💊, a combined ARG1/ARG2 inhibitor discovered at #Molecure, has been published 🖋️ in Molecular Cancer Therapeutics @MCT_AACR, a journal of the American Association for Cancer Research.

Read the full study here: https://t.co/5V35E7gc6R https://t.co/B9zC2EF4Z3

0

16

2

1

1K

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users